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Abstract
To enter target cells HIV-1 uses CD4 and a coreceptor. In vivo the coreceptor function is provided either by CCR5
(for R5) or CXCR4 (for X4 HIV-1). Although both R5 and X4 HIV-1 variants are present in body fluids (semen, blood,
cervicovaginal and rectal secretions), R5 HIV-1 appears to transmit infection and dominates early stages of HIV
disease. Moreover, recent sequence analysis of virus in acute infection shows that, in the majority of cases of trans-
mission, infection is initiated by a single virus. Therefore, the existence of a “gatekeeper” that selects R5 over X4
HIV-1 and that operates among R5 HIV-1 variants has been suggested. In the present review we consider various
routes of HIV-transmission and discuss potential gatekeeping mechanisms associated with each of these routes.
Although many mechanisms have been identified none of them explains the almost perfect selection of R5 over
X4 in HIV-1 transmission. We suggest that instead of one strong gatekeeper there are multiple functional gate-
keepers and that their superimposition is sufficient to protect against X4 HIV-1 infection and potentially select
among R5 HIV-1 variants. In conclusion, we propose that the principle of multiple barriers is more general and not
restricted to protection against X4 HIV-1 but rather can be applied to other phenomena when one factor has a
selective advantage over the other(s). In the case of gatekeepers for HIV-1 transmission, the task is to identify them
and to decipher their molecular mechanisms. Knowledge of the gatekeepers‘ localization and function may enable
us to enhance existing barriers against R5 transmission and to erect the new ones against all HIV-1 variants.
Introduction
To fuse with the membranes of target cells, human
immunodeficiency virus type 1 (HIV-1) uses as recep-
tors two plasma membrane molecules, CD4 and a sec-
ond one that for historical reasons is called a
“coreceptor” [1-3]. For HIV-1 the coreceptor function
can be provided by two different receptors, C-C chemo-
kine receptor type 5 (CCR5) or C-X-C chemokine
receptor type 4 (CXCR4), these have a normal physiolo-
gical function serving as chemokine receptors (cyto-
kines). HIV-1 variants that use the CCR5 coreceptor are
called R5, those that use CXCR4 are called X4, whilst
those that can use both are designated R5X4 (or dual
tropic) [4]. Although both R5 and X4 HIV-1 variants
are present in body fluids (semen, blood, cervicovaginal
and rectal secretions), with a few exceptions R5 HIV-1
appears to transmit infection and dominate the early
stages of HIV disease whilst X4 HIV-1 evolves at later
stages. If and when this evolution takes place, it is asso-
ciated with a more rapid loss of CD4 T cells and accel-
erated progression to the acquired immunodeficiency
syndrome (AIDS) (reviewed in [5]).
Until recently it was not clear whether X4 evolves
from transmitted R5 as a result of env mutations, or
that X4 was initially transmitted but its replication was
restricted during the early stages of the HIV disease.
Recent genetic studies of HIV-1 variants at the earliest
stages of HIV-1 infection have enabled researchers to
reconstruct the HIV-1 variants that were initially trans-
mitted [6,7], known as transmitted/founder virus (TF
virus). These studies confirmed that only R5, and in a
few instances R5X4 HIV-1, but not X4 HIV-1 are trans-
mitted. Therefore, it is reasonable to suggest the exis-
tence of a “gatekeeper” that nearly always selects
transmission of R5 over X4 HIV-1.
Such a gatekeeping phenomenon may not only select
R5 over X4 but may operate among R5 HIV-1 variants
as well. Recent studies on TF virus indicate that, in the
majority of cases, infection is transmitted by a single R5
viral isolate [6,7]. It was hypothesized that these
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provide advantages for transmission over the majority of
R5 virus in biological fluids. If so the gatekeeping
mechanism may be even more selective than previously
anticipated.
Understanding the scope of potential gatekeeping
mechanisms is important not only from the point of
view of basic science but also for practical reasons.
Indeed, if only selected HIV-1 viruses can transmit
infection, microbicides (or preventive vaccines) should
specifically target these particular variants, provided that
such a strategy will not allow transmission of other
HIV-1 isolates. Also, understanding the molecular
mechanisms of the selective prevention of transmission
of some of the HIV-1 variants, may empower us with
the necessary knowledge to expand such gatekeeping to
those HIV-1 variants that transmit infection, creating
new preventive strategies.
Below, we briefly describe the history of the develop-
ment of the HIV-1 coreceptor tropism concepts, various
patterns of HIV-1 transmission, and the possible
mechanisms of gatekeeping.
R5 and X4 HIV-1: Development of the concept
The controversial history of the discovery of HIV-1 has
been the subject of many reviews and has recently been
well described by Vahlne [8]. HIV-1 was first called
Human T-lymphotropic virus (HTLV-III) or lymphade-
nopathy-associated virus (LAV) by two competing
groups. CD4 was shown to be the principle receptor for
HIV-1 following a series of observations. These
included: the observed decline in peripheral CD4+ T
cells in homosexual patients presenting a “newly
acquired cellular immunodeficiency syndrome” (AIDS)
[9], the ability of HIV-1 isolated from these patients to
infect CD4 T cells [10,11], the blockade of HIV-1 infec-
tion in vitro by anti-CD4 antibodies [12], and infection
of virus-resistant human cells following transfection
with the human CD4 gene (hCD4) [13]. However it was
found that mouse cell lines transfected with hCD4, were
not susceptible to infection. This observation suggested
that additional human factors were required for HIV-1
infection. The failure of hCD4 transfected mouse cells
to form syncitia (cell-cell fusion) with the HIV-1 produ-
cing human H9 cell line suggested that viral entry was
the rate limiting step [14]. Furthermore, the inability of
hCD4 positive squamous cell carcinoma (SCL1) and
astroglial cells (U87MG) to form syncitia with cells
expressing HIV-1 envelope demonstrated that infection
with the newly-discovered virus required secondary
receptor(s) in addition to CD4. These results led to the
identification of the HIV-1 co-receptors in 1996. Here,
we review some of the work that led to their discovery
and the understanding that distinct biological properties
of HIV-1 in patients and in vitro are due to the exis-
tence of distinct viral strains using different cellular
coreceptors.
Envelope polymorphism meets clinical status
The envelope protein gp120 was identified as the viral
partner interacting with CD4, and the regions involved
in this interaction were mapped by site directed muta-
genesis and antibody interference (for review see [15]).
Within two years of the discovery of HIV-1, the nature
of the interactions between CD4 and the viral envelope
gp120 as well as the genetic diversity of HIV-1 isolates,
especially in their envelope-encoding gene, were begin-
ning to be understood [16-18]. However, there was no
biological correlate for this diversity. The development
of diagnostic-tests measuring the presence of the viral
core protein p24 [19], anti-HIV-1 antibodies [20-24],
and the activity of viral reverse transcriptase (RT) [25],
identified HIV-1 infected subjects with a wide spectrum
of clinical manifestations. The first attempt to stage the
clinical status of HIV-1-infected patients came from
Robert Gallo’s group [26] which proposed in 1985 a
6-stage classification of patients positive for gp41 anti-
bodies. This work revealed a linear progression from
asymptomatic subjects to AIDS patients. However, the
lack of viral isolates at the time prevented any correla-
tion of these different stages of disease progression with
in vitro biological properties of the virus. It was Eva
Maria Fenyo and her associates who first showed that
viruses isolated from asymptomatic patients were slow
to replicate in in vitro culture and yielded low RT levels,
while viruses isolated from patients at an advanced stage
of disease were fast to replicate and yielded high levels of
RT [27]. In this seminal work, the authors noted that
“The relation between the severity of illness and in vitro-
replication potential of viruses suggests that during the
course of an infection, selection may occur for variants
that replicate efficiently in CD4 T cells”.T h i s“fast/high”,
“slow/low” dichotomy of viral isolates constituted the
first attempt at classifying the biological properties of
HIV-1 and was later confirmed by other groups [28,29]
working with patients’ isolates and HIV-1 molecular
clones [30-34].
Extension of the classification of HIV-1 by additional
biological properties
Later work identified that many viral isolates from
chronically infected patients-induced syncytia, the fusing
of HIV-1-infected cells with other CD4 T cells in vitro
[35] . This was also detected in brain autopsies from
HIV-1 infected patients [36]. This gave rise to a second
HIV-1 classification based on the ability of certain viral
isolates to induce syncytia in culture. Tersmette et al.
[37] reported that all viruses isolated from AIDS
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more than 80% of viruses isolated from asymptomatic
patients were not. The former isolates were called syn-
cytia-inducing isolates (SI) and the latter were called
non-syncytia inducing (NSI) isolates. SI isolates could be
easily differentiated from NSI isolates based on their
ability to replicate in H9 cells. The discovery that similar
isolates described earlier by Fenyo [27] also showed this
phenotype lead to adoption of the SI/NSI dichotomy as
an accepted classification for HIV-1 isolates [38-42].
The development of culture methods to differentiate
blood monocytes into macrophages susceptible to HIV-
1 infection [43] and the use of monocytic indicator cell
lines [44] paved the way to the adoption of yet another
classification of HIV-1 isolates based on their ability to
infect macrophages/monocytes. Isolates able to infect
these cells were called macrophage-(M)-tropic. Although
M-tropic HIV-1 isolates could not grow in T-cell lines
[45], they readily infected primary T cells [46].
As a result, viral isolates were then classified according
to their efficiency of replication (fast/high, slow/low),
their ability to induce syncytia (SI/NSI) in T cell-lines,
and their ability to replicate in T cell-lines or macro-
phages (T-tropic/ M-tropic). Most primary isolates irre-
spective of their rapid/high, syncytium-inducing
phenotype or slow/low, non-syncytium-inducing pheno-
type were able to infect both primary T cells and mono-
cyte-derived macrophages in vitro, although with
unequal efficiencies [47].
Biological implications of the viral phenotypes
The ability of SI isolates, defined on PBMCs, to replicate
in lymphoblastoid T cell lines, H9, MT-2, and MT-4
[48,49], led to the interchangeable use of the terms “SI”
and “T- tropic”. Yet, already from the first report
describing SI viruses [37] it was clear that the two terms
were not interchangeable since not all SI isolates were
T-cell-line tropic. Later, the discovery of co-receptors
clarified this misconception.
The fact that fast-high, SI, T-tropic viruses were iso-
lated at late stages of disease when patients showed
signs of immune suppression and had a declining num-
ber of CD4 T cells in their blood, lead to the notion
that these isolates were highly cytopathic [37,40,45,50].
In contrast, slow/low, NSI, M-Tropic viruses, isolated
initially from asymptomatic patients with no sign of
CD4 decline shortly after infection, were thought to be
less cytopathic. This notion also turned out to be
wrong. In clade B, T-cell-line tropic viruses are only
found in 50 % of patients who progress to AIDS
[39,49-51] . Furthermore, NSI viruses can be isolated at
all stages of HIV disease [39] and therefore caused CD4
T cell decline and disease progression in patients whose
viruses did not convert to SI. In addition, the apparent
lack of effects of NSI viruses on CD4 T-cell depletion
was restricted to peripheral blood [52], while significant
CD4 T-cell depletion occurred in the rectal mucosa [53]
and duodenum in asymptomatic patients.
The quest for the co-receptors
Because infection of macrophages by M-tropic virus
could be blocked by anti-CD4 antibodies [54], and
because the cellular tropism of HIV-1 could be mapped
to specific regions of gp120 [55,56], it became clear that
this viral protein recognized the same receptor, CD4, on
the cell surface of both T cells and macrophages. How-
ever, it was proposed that secondary receptors differen-
tially expressed on macrophages and T cell lines might
determine infection of these cells by T- and M-tropic
virus [57]. The search for these receptors was underta-
ken using multiple approaches as described above
[58-60]. The co-receptor for SI virus was identified by
the group of Edward Berger and colleagues [61] as a
7-transmembrane segment G protein-coupled receptor,
named “fusin”, This receptor was soon recognized as the
CXCR4 chemokine receptor for Stroma cell Derived
Factor-1 (SDF-1) [62,63].
The co-receptor for slow/low viruses also turned out
to be a chemokine receptor. This became clear in light
of a seemingly unrelated publication by Paolo Lusso et
al [64] showing that the CC-chemokines Macrophage
Inflammatory Protein (MIP)-1a,M I P - 1 b and Regulated
upon Activation Normal T-cell Expressed and presum-
ably Secreted (RANTES) inhibited the replication of
M-tropic isolates but not T-tropic isolates. Three differ-
ent groups [65-67] cloned the CC-chemokine receptor 5
(CCR5), which binds these three CC chemokines and by
linking all these studies together, several groups identi-
fied CCR5 as being the missing co-receptor for M-tropic
viruses [1-3,68]. Thus, in 1996, HIV-1 cellular tropism
had finally found a molecular basis: M-tropic viruses
(NSI slow/low) were shown to use CCR5 as a coreceptor
whereas T-tropic (SI, rapid/high) isolates used CXCR4
[69,70]. Dual tropic viral isolates and their derived
clones able to infect primary T cells, T cell lines and
macrophages were shown to use both CCR5 and
CXCR4 [71]. Although, other chemokine receptors were
shown to have HIV-1 co-receptor activity when
expressed in cell lines in vitro (see Berger et al [72]), it
seems that in vivo, only CCR5 and CXCR4 are used to
infect cells (with the possible exception of CCR8 [73],
and BONZO/STRL33 [74]), The importance of chemo-
kine receptors in HIV-1 infection is demonstrated by (i)
an almost absolute [75] resistance to infection of indivi-
duals that have a homozygous mutation for CCR5 (delta
32) [76] (although, two cases of infection of such
patients by dual tropic CXCR4/CCR5 HIV-1 have been
reported [77,78]), (ii) slow disease progression in patient
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that the switch from CCR5-tropic to CXCR4-tropic
HIV-1 is associated with a massive CD4 T cell depletion
and a rapid progression to AIDS. However without a
switch to X4, R5 HIV-1 variants may undergo mutations
that increase their pathogenicity in the course of HIV
disease [80].
A new classification for HIV-1
The discovery of chemokine receptors used by HIV-1
led to the establishment of a new classification of HIV-1
[4] which relies solely on coreceptor usage. As men-
tioned CCR5-using HIV-1 variants are called R5,
whereas CXCR4 using HIV-1 variants are called X4; var-
iants that use both co-receptors are called R5X4. While
this classification has been widely adopted, it was also
recommended that the type of cells used to passage
viral stocks, such as T-cell line-adapted (TCLA) for
viruses passaged through a T cell line, should also be
indicated. The latter recommendation has somehow
been forgotten, which led to a challenge of this mono-
parametric HIV-1 classification [81]. Moreover, whilst
“dual-tropic” HIV-1 variants can utilize both CCR5 and
CXCR4 in transfected cell lines, they are often only able
to effectively use one of these two coreceptors in tissue
displaying either R5 or X4 mono-tropism [82]. Thus,
the widely-adopted, monoparametric classification of
HIV-1 variants may be modified in the future when
more is known about the mechanisms of HIV-1 trans-
mission and pathogenesis.
A few questions answered
The discovery of HIV-1 coreceptors explained some of
the in vitro properties of HIV-1 and facilitated rigorous
analysis of their role in HIV-1 fusion. This analysis high-
lighted that all HIV-1 variants have the potential to
induce syncitia provided that the target cells express suf-
ficient levels of CD4 and the relevant co-receptor used
by that virus. Indeed the reason M tropic viruses did
not induce syncytia in H9 and MT2 T cell lines was due
to the lack of CCR5 expression on these cells. Further-
more in contrast to the wide distribution of CXCR4
among different subsets of naïve lymphocytes, cells
expressing CCR5 constitute a small fraction of periph-
eral blood T cells limited to memory T cells [83]. In
lymphoid tissues CCR5 expression is also confined to a
fraction of memory T cells [84] that constitute less than
15% of CD4 T cells [85]. The low abundance of CCR5
expressing CD4 T cells in blood accounts for the appar-
ent low cytopathicity of R5 viruses. However, for cells
expressing CCR5, the R5 variants were shown to be as
cytopathic as their X4 HIV-1 counterparts for CXCR4-
expressing CD4 T cells and were responsible for the
depletion of CCR5 expressing CD4 T cells [85].
Accordingly, in the small intestine, where the majority
of mucosal T cells express CCR5, infection with CCR5-
tropic HIV-1 causes massive depletion of CD4 T cells
[53,86-89].
The individual variability in the abundance of CCR5-
expressing T lymphocytes [90] and macrophages may
determine whether an individual progresses to AIDS
with the dominance of R5 HIV-1 or undergoes a switch
to X4 HIV-1 that triggers accelerated progression of the
disease.
HIV-1 transmission R5 vs. X4: Gatekeeping
It seems that X4/R5 gatekeeping (that is prevention of
X4 HIV-1 from infecting and/or disseminating in the
human body at the early stages of HIV-1 infection)
belongs to a rare class of almost perfect biological phe-
nomena. Among multiple reported HIV-1 transmission
events via sexual acts (between males and females or
between males) or through intravenous injection, at the
early stages of infection R5 HIV-1 was ubiquitously
found. Such precision suggests the existence of a near
perfect barrier that selects against X4 HIV-1 transmis-
sion. Where are these gatekeepers and what are their
mechanisms? There is no definitive answer, however we
discuss below potential mechanisms and points at which
selection may occur according to the different routes of
transmission .
Intra-vaginal transmission
World-wide the majority of HIV-1 transmission occurs
through heterosexual intercourse. Women have increas-
ingly bourn the brunt of HIV infection mainly through
vaginal intercourse and this route of infection has been
the one most widely studied in various experimental
models. In vaginal infection genital mucosa serves as the
first port of entry for HIV-1 and the mucosal barrier is
probably one of the gatekeepers not only for X4 HIV-1
but for other HIV-1 variants as well [91].
In vaginal intercourse HIV-1 is ejaculated with semen
and transverse mucus that covers the mucosa of the
lower female genital track. To establish infection HIV-1
needs to access and infect target cells (lymphocytes,
macrophages, possibly dendritic cells (DC), and Langer-
hans cells (LCs) in particular) in the local mucosa, and
be transmitted to the draining lymph nodes where it
undergoes rapid replication before being disseminated
throughout the entire body. It is believed that a major
site for HIV-1 transition in the female genital tract is
the cervix, especially the endocervix and the transitional
zone, which are covered by a single-layered columnar
epithelium. Such a layer is less protective against HIV-1
than the stratified epithelia of the vagina [92,93],
reviewed in [94]. Also, the endocervix, together with the
transition zone, contains a high number of potential
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transmission to women with a congenital absence of a
cervix has been reported [96]. SIV has also been trans-
mitted intravaginally to rhesus macaques after hysterect-
omy [95,97,98].
The fluid of the lower female genital tract which cov-
ers the genital epithelia provides the first potential bar-
rier for the virus on its way to dissemination. Female
genital fluids are different in different parts of the geni-
tal tract: the vagina is covered by an exudate, which
enters through the stratified epithelia that cover this
organ. The barrier function of this fluid against HIV-1
has not been thoroughly studied. It is believed that vagi-
nal stratified epithelia provides a significant mechanical
barrier to many viruses. Furthermore, the exudate is
increased with sexual arousal and therefore its composi-
tion may significantly change during sexual intercourse.
Nevertheless, virus can penetrate the superficial layers of
the stratified epithelium and this may be sufficient to
reach superficial Langerhans cells and CD4 T cells, and
would be enhanced by any micro or macro lesions in
this epithelium.
Higher in the genital tract, the epithelia are covered by
true mucus produced by cervical secretory cells. Mucin
is the main mucus component and in the endocervix it
is mainly a product of two genes: MUC4 and MUC5B
[99]. Mucus can protect underlying epithelia by two
mechanisms: decreasing HIV-1 infectivity via various
soluble factors present in it and/or by temporarily trap-
ping virions in the protein mesh, thus slowing their
movement by several orders of magnitude compared
with water [100-103]. Since HIV-1 is a fragile virus and
cannot remain at normal temperature outside of cells
for a long time, its infectivity may be significantly
decreased if mucus slows viral penetration. Moreover,
during vaginal HIV-1 transmission the acidity of mucus
is decreased because of the mixture with alkaline semen.
This mixture is less viscous than pure mucus, and the
diffusion rate of virions in it is only 15 times slower
than in water [101]. Nevertheless, this slowing of HIV-1
penetration may be sufficient for significantly reducing
HIV-1 infectivity. Since semen contains not only free
virions but also lymphocytes that carry HIV-1 [98],
trapping these lymphocytes in mucus may also reduce
HIV-1 transmission by these carriers.
Chemical defense against HIV-1 is mediated by mucus
soluble factors, in particular by chemokines produced by
epithelial cells. In some experimental models epithelia
was shown to constitutively produce a CXCR4-binding
chemokine, SDF-1, thus selectively reducing X4-HIV-1
transmission [104,105]. Also, cervical mucus contains
beta defensins that may inactivate HIV-1 on its way to
the epithelia (for review see [106]). Defensins are
secreted by epithelial cells under the hormonal control
of oestradiol and progesterone [107,108]. Some of these
defensins are more restrictive against X4 [58,109-112].
However, others do not significantly differentiate
between X4 and R5 HIV-1 [109,110]. Microbicidial
enzymes, surfactant proteins and complement present
in cervical mucus (see[94]), as well as other as-yet
unknown soluble factors observed in proteomics experi-
ments [113], may contribute to the gatekeeping effect.
As a result, mucus and mucins suppress HIV-1 in inhi-
bitory assays [114]. The two protective mechanisms of
mucus may work synergistically, as even temporary trap-
ping of HIV-1 and HIV-1-infected cells provide a longer
exposure to the soluble factors present in mucus as well
as to anti HIV-1 antibodies that may have been gener-
ated in one of the partners.
Additional gatekeeping effects of mucus may be
affected by the difference in the surface charges between
R 5a n dX 4H I V - 1 .T h eV 3l o o pi ng p 1 2 0o fX 4H I V - 1
has more exposed cationic charge than R5 HIV-1[115].
In principle, this may result in a stronger binding of X4
HIV-1 to the polyanionic mucin and a preferential clear-
ance of these viruses, or at least impairment of their
infectivity. However, dilution of cervical mucus by
semen may make this effect negligible. The higher catio-
n i cc h a r g e so fX 4H I V - 1g p 1 2 0m a ya l s om a k et h e s e
viruses more prone to bind to heparin sulphate proteo-
glycans that cover mucosal surfaces and thus may work
as a sink for these viruses [116,117]. However, these the-
oretical considerations regarding the difference between
X4 and R5 HIV-1 have to be tested experimentally.
Also, it has been shown that agrin, which plays an
important role in establishing viral synapses through
which HIV-1 can pass from one cell to another, binds
preferentially to R5 HIV-1[118].
Another level of complexity in vaginal HIV-1 trans-
mission is that both mucus and cervical tissue charac-
teristics are not constant but rather undergo changes
during the menstrual cycle. A window of infectivity at 7
to 10 days post-ovulation, when the defense mechanisms
are at a low level, has been identified [119].
Viral particles that go through the cervical mucus
reach the epithelial layer. The epithelial layer itself
seems to be an efficient mechanical barrier against HIV-
1 and other pathogens [95]. Also, epithelial cells of the
lower genital tract are not infected by HIV-1 in vivo.
Although these cells can express coreceptor molecules,
they do not in general express the HIV-1 receptor CD4,
The possible exception to this rule is the expression of
CD4 by uterine epithelial cells at the proliferative phase
of the menstrual cycle [120]. However, under laboratory
conditions infection of epithelial cells has been reported
[121], and a role in HIV-1 transmission has been
ascribed to them [122]. Nevertheless, it is believed that
for efficient infection it is necessary for HIV-1 to bypass
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lesions that commonly occur as a result of various infec-
tions and probably environmental factors. Also, microle-
sions may be generated as a result of coitus [123].
Experiments with cervical explants and fluorescence-
labeled HIV-1 showed that HIV-1 penetrates genital
mucosa similarly to inert particles, that is, via the gaps
between cells (T. Hope, personal communication).
When virus encounters and infects its first natural cellu-
lar targets, predominantly lymphocytes beneath or
within the epithelial layer, it may be efficiently dissemi-
nated in cell-associated form from cell to cell through
viral synapses which seems to be more efficient than
cell-free virus transmission [118,124,125]. This early
stage of HIV-1 transmission when few founding cells
are infected is critical for the further dissemination of
HIV-1 through the body [94]. Surprisingly, although R5
HIV-1 readily infects macrophages in vitro,t h ef i r s t
(founding) infected cells seem to be CD4 lymphocytes
[126].
To characterize HIV-1 targets in cervical tissue more
thoroughly, it is necessary to apply multi-color flow
cytometry. Recently a protocol of cervical tissue
dissociation into single cells that retain their antigenic
characteristics has been developed [127], thus enabling a
thorough analysis of cervical mucosal lymphocytes using
flow cytometry [128]. It was found that cervical tissue is
particularly rich in CCR5-expressing CD4 lymphocytes,
which make this tissue potentially more susceptible to
R5 HIV-1 infection than lymphoid tissue [128]. Accord-
ingly, cervico-vaginal explants express a strong gate-
keeping function: on average, dramatically more R5
HIV-1 is released from the ex vivo-inoculated cervico-
vaginal tissues than X4. Moreover, in a relatively small
fraction of tissues that were capable of replicating X4
HIV-1 a correlate was found: a higher presence of early
differentiated CD4 lymphocytes [128]. The relation of
this fraction to the gatekeeping function of cervical
tissue remains to be understood.
Earlier, it was reported that CD4+/CCR5+ cells are
consistently detected within the stromal papillae that
penetrate the epithelial layer; this location probably
makes them easy targets for HIV-1 [129]. Also, it was
reported that the levels of CCR5 mRNA in the cervix
were up to 10-fold higher than those of CXCR4 mRNA
[130]. However, opposite results have been also reported
[131]. The level of mRNA for surface antigens is not
necessarily translated into the level of expressed pro-
teins. It was shown that cervical lymphocytes express
not only CCR5 but CXCR4 as well [128].
Beneath and within the epithelial layers are situated
DCs and LCs repectively, which may protrude their den-
drites through the layer to the lumen. Normally, these
cells capture, and process antigens and deliver them to
the draining lymph nodes where they present them to
T cells. In HIV-1 infection these cells may bind and
deliver HIV-1 from the lumen to the draining lymph
node. Although it was firmly established that cervico-
vaginal LCs are able to transfer HIV-1 in vitro, it is not
clear whether these cells can be productively infected in
vivo [132]. Nevertheless, they may represent one of the
significant elements of gatekeeping as these cells express
among other HIV-1-binding molecules, CD4 and CCR5
but not CXCR4 [133,134]. Also at various sites these
cells may have different levels of expression of various
HIV-1 coreceptors, providing gatekeeping for particular
viruses. Cells that, upon binding antigens or upon infec-
tion with a virus, are capable of moving out of the tissue
are collectively called migratory cells [135]. Such cells
consist of a heterogeneous population with very differ-
ent features.
The entire list of such cells is not yet known. Their
infection with HIV-1 in cervico-vaginal tissue was
demonstrated using explants (see [136]). Macrophages
do express CCR5 [137] and are particularly susceptible
to R5 HIV-1 infection in vitro and ex vivo.T h u s ,t h e y
could also play a significant role as gatekeepers against
X4 HIV-1, although in tonsillar explants macrophages
are infected by X4 viruses [138]. However, studies of
early events of infection in non-human primates with
SIV did not reveal infected macrophages [126]. Further-
more, TF virus appears to infect macrophages poorly.
Whether high expression of CCR5 and early macro-
phage infection with HIV-1 reflects the situation in
humans in vivo or represent an “artifact” from using iso-
lates with high macrophage tropism in the explants sys-
tem, remains to be clarified.
Thus, although cervical mucosa performs gatekeeping
functions, it is obvious that this performance is not per-
fect and that X4 HIV-1 can penetrate this barrier,
although much less efficiently than R5 HIV-1.
Penile transmission
Globally 80% of men acquired HIV-1 infection from vagi-
nal intercourse, i.e. through the penis (see [136,139]).
This is also true when infection is acquired through
insertive anal intercourse. However, mechanisms of HIV-
1 acquisition through the penis are even less understood
than for vaginal transmission in women. Nevertheless, it
is clear that gatekeeping mechanisms operate for this
route of infection, since R5 HIV-1 also starts infection
and dominates its early stages in men.
During intercourse the penis comes into close contact
with the vagina and is bathed in vaginal fluid. Thus, it is
reasonable to assume that all the above-mentioned pro-
tective barriers that are associated with female genital
tract fluids and that protect cervical epithelia from viral
infection, including barriers that are selective for R5
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nal route of infection, genital fluid may be the first
“gatekeeping” mechanism in penile infection. In the
course of vaginal intercourse, vaginal fluids are mixed
with (pre-) ejaculate. The latter increases mucosal pH
and also contains various soluble factors that may dra-
matically change the characteristics of the mucus.
R e c e n t l y ,i tw a sr e p o r t e d[ 1 2 4 ]t h a ts u c ham i x t u r e ,
unlike each fluid separately, has an inhibitory effect on
HIV-1 infectivity. Whether this effect is different for R5
and X4 HIV-1 has not yet been determined.
After penetrating the mucus or the mixture of mucus
and semen, HIV-1 reaches the penile epithelium. What
part of the penis is the most vulnerable to HIV-1 transmis-
sion? Clinical trials performed over the last several years
have shown that circumcision greatly reduces the prob-
ability of penile HIV-1 transmission. Thus, the foreskin (or
other parts of penis that may be indirectly affected by fore-
skin removal) seems to play a significant role in transmis-
sion of HIV-1. The outer foreskin is heavily keratinized
and therefore is considered well protected against patho-
gen penetration. It was shown [124] in ex vivo experiments
with foreskin explants that it is indeed the case: HIV-1
does not penetrate the outer foreskin well. In contrast, the
inner foreskin and frenulum are covered with a much
thinner layer of keratin. Accordingly, in ex vivo experi-
ments the inner foreskin was shown to be vulnerable to
HIV-1 penetration [124]. However, it was recently shown
that keratinization of the outer and inner foreskin is not
statistically different, and other mechanisms for the differ-
ential permeability of these two parts of the foreskin
should be considered [140].
During erection the foreskin is stretched out, revealing
its inner aspect, which becomes accessible both to cell-
free HIV-1 in the vagina as well as to HIV-1-infected
cells that may be situated on the surface of the female
genital tract. Another factor that may make the foreskin
an important portal of HIV-1 entry is the abundance of
HIV-1 cellular targets. The entire foreskin is rich in var-
ious cells that constitute potential HIV-1 targets includ-
ing: CD4 T lymphocytes, macrophages, and LCs
[133,139,141,142]. In ex vivo experiments and in autop-
sied tissues [139] infection was revealed in CD4 T lym-
phocytes and in LCs. However, in the outer foreskin
these cells are thought to reside beneath the highly kera-
tinized epithelia and are less accessible for HIV-1. In
contrast, in the inner foreskin where the keratin layer is
thin, LCs are probably the first target cells that HIV-1
encounters. Here LCs are more abundant and nearer
the surface and thus cells are more likely to protrude
their dendrites through the epithelial layer towards the
outer surface.
Foreskin LCs seem to play a significant role in gate-
keeping. In experiments with foreskin explants these
cells selectively transfer R5 but not X4 HIV-1 to indica-
tor cells. Another gatekeeping process may stem from
the fact that the average density of CCR5-expressing
cells in the inner foreskin is 10-fold higher than that of
CXCR4-expressing cells [139]. However, the extent of
individual variations in this parameter remains to be
confirmed in a large group of subjects.
Although keratinized epithelium is highly protective,
various abrasions, lesions due to STDs, as well as micro-
trauma, provide access for HIV-1 to the target cells that
reside beneath the surface of the organ. Lesions or
microtrauma would also render the outer foreskin and/
or shaft of the penis vulnerable to HIV-1 infection, pro-
viding access to an abundance of cells expressing CD4,
as well as CCR5 and CXCR4. However, even when HIV-
1 gets direct access to sub-epithelial layers, R5 HIV-1
seems to find more targets than X4 HIV-1 since on
average cells expressing CCR5 are situated in the outer
foreskin, glans, and frenulum closer to the surface than
cells expressing CXCR4. Also the average density of
CCR5-expressing cells in the outer foreskin is higher
than that of CXCR4-expressing cells [139]. All these fea-
tures of the foreskin clearly indicate that whether HIV-1
enters through the inner foreskin or through defects in
the keratin layer into the outer foreskin, the barriers
against infection are selective and protect the foreskin
against X4 HIV-1 infection more efficiently than R5
HIV-1.
Although the foreskin seems to be an important site
of HIV-1 entry, circumcised men also acquire HIV-1
through the penile route. Thus, other sites of entry
besides the foreskin exist. The glans penis in both cir-
cumcised and uncircumcised men is covered by highly
keratinized squamous epithelia and seems to be rela-
tively protected against HIV-1 entry in the absence of
lesions or microtrauma. In contrast, the penile urethra
is less protected as it is covered by a non-keratinized
columnar epithelium that is narrowly stratified at the
meatus and is also populated with CD4 T lymphocytes
and macrophages [93]. Both CXCR4 and CCR5 mRNA
have been isolated from urethra swabs in equal amounts
[143]. However, it is difficult to translate these data into
the relative abundance of CCR5- and CXCR4-expressing
cells on the basis of the mRNA measurements.
In summary, on its way to dissemination within the
body via the penile route of infection, HIV-1 has to
overcome many protective barriers. Some of these bar-
riers can discriminate between R5 and X4 HIV-1 and
are higher for the latter.
Gastro-intestinal mucosal transmission
The probability of infection through receptive anal inter-
course is much higher than through vaginal or penile
intercourse. These data were confirmed in experiments
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under controlled laboratory conditions [144]. Thus, it
seems that fewer protective barriers exist for this route
of HIV-1 transmission. Nevertheless, the gastro-intest-
inal route of transmission also exhibits a gatekeeping
mechanism against X4 HIV-1.
The vulnerability of the colorectum to HIV-1 infection
stems from two major factors. First, a single layer of
columnar epithelium separates the lumen from the
inner layers. This layer is fragile and maybe damaged
during intercourse. Also, epithelial cells, although not
infectible by HIV-1, may be damaged directly by the
virus violating the layer’s integrity [145]. Second, lym-
phocytes in colorectal tissue are constitutively activated,
providing HIV-1 cell targets that efficiently replicate
virus [90,146,147], facilitating its dissemination. This is
probably one of the reasons why this tissue tissue is one
of the first that is damaged by HIV-1 infection, irrespec-
tive of the transmission route [86,148]. Although fragile
and not providing sufficient mechanical protection, col-
orectal epithelium provides some biological protection.
Among other soluble factors it secretes chemokines, in
particular stromal-derived factor 1 (SDF-1) [104], the
natural ligand for CXCR4 that in vitro selectively sup-
presses X4 HIV-1 but not R5 HIV-1 infection [62].
Even with intact epithelia, HIV-1 may be transmitted
through the epithelial layer by transcytosis [105,149] or
transferred by DCs [150]. Also, more colorectal CD4 T
cells express CCR5 than do tonsillar CD4 T cells [147].
However, colorectal explants can support replication of
both R5 and X4 HIV-1, although X4 less efficient, thus
the barrier to X4 infection is unlikely to be absolute
[90]. Nevertheless, colorectal tissue per se seems to be
more vulnerable to R5 HIV-1 infection than secondary
lymphoid tissue but can be efficiently infected by X4
HIV-1 as well [90].
HIV-1 transmission through oral sex and also mother-
to-child transmission are most likely to occur through
the gingeva or tonsils. The latter infection is mediated
by swallowing HIV-containing fluids in the birth canal
or with breast milk. There is a gatekeeping mechanism
operating at the upper gastrointestinal site, and again R5
has an advantage over X4 HIV-1 [151-155]. One of the
important defense mechanisms in oral sex is the anti-
HIV-1 activity of the saliva [156]. Like vaginal mucus,
saliva can trap HIV-1 [157]. However, this mechanism
does not seem to be selective for R5 and X4 HIV-1.
Also, saliva decreases HIV-1 infectivity because of the
presence of various soluble factors [158], including pro-
teases [159] and defensins (see [160]). As discussed
above, some of the latter suppress X4 more efficiently
than R5 HIV-1 providing a basis for another X4 HIV-1
gatekeeping barrier. Vertical transmission mediated by
swallowing breast milk may well occur through infection
via the tonsils or other lymphoid tissue associated with
the Waldeyer’s ring. Indeed exposure of the tonsils to
SIV in neonatal macaques is sufficient to establish infec-
tion [161].
Another gatekeeping mechanism may be associated
with transcytosis and related to the fact that epithelial
cells of the small intestine preferentially express CCR5
rather than CXCR4 [147]. Exposure of the small intes-
tine may occur if any virus or infected cells can survive
acidification of the stomach, most likely in the first
hours to days following birth. It is not clear to what
extent this potential pathway for HIV-1 penetration of
the epithelial barrier can discriminate between R5 and
X4 HIV-1 [105,149]. In in vitro experiments it was
reported that primary intestinal (jejunal) epithelial cells
were able to transfer R5 but not X4 HIV-1 through
trancytosis to indicator cells [162].
A few cases of early detection of X4 HIV-1 in vertical
transmission have been reported [152,155,163]. How-
ever, in these cases it was not clear whether X4 HIV-1
was actually transmitted or evolved from the earlier-
transmitted R5 HIV-1. Establishment of a phylogenic
relationship between mother’sa n dc h i l d ’sv i r u s e s
is required to distinguish between the two above-
mentioned possibilities. In the absence of such work, it
was widely believed that the gatekeeping mechanisms of
vertical transmission are as tight as those of horizontal
transmission. When the phylogenic analysis of the
mother-to child transmitted variants has been per-
formed it was found that X4 variants always evolves
from the transmitted R5 HIV-1 [164].
However, a recent study has been published that
demonstrated the transmission of X4 HIV-1 (and dual-
tropic R5X4 variants) from five Ugandian mothers to
their babies [165]. As was shown for cases when X4
evolved as a result of R5 HIV-1 mutation, babies with
X4 HIV-1 dominance quickly progress to AIDS. In the
case referred to above, these babies died earlier than
those to whom R5 HIV-1 was transferred [165].
In conclusion multiple mechanisms for preferential
transmission of R5 HIV-1 through the gastrointestinal
route have been reported. Although the published data
are somewhat controversial, these mechanisms may
include: preferential secretion of chemokines that bind
to CXCR4 rather than CCR5, the higher level of CCR5
expression, and potentially, preferential transcytosis.
However, none of these mechanisms alone seems to
explain the high efficiency of the gastrointestinal “gate-
keeper” in protection of X4 HIV-1 transmission
Post-mucosal gatekeepers
Following on from the discussion above, although several
somewhat efficient gatekeepers exist at the mucosal
portals of HIV-1 entry, they are not perfect. Everything we
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spite of them, X4 HIV-1 should be capable of entering the
human body, although less efficiently than R5 HIV-1.
However, in vivo X4 infection rarely occurs, except in a
few recently reported cases of vertical transmission [165].
Thus, it appears that there are additional post-mucosal
gatekeeping mechanisms. This suggestion is supported by
the fact that if HIV-1 bypasses mucosal barriers and is
delivered directly (intravenously, with a non-sterile syringe
needle or with contaminated blood in a blood transfusion)
it is again R5 HIV-1 that is transmitted and that dominates
early stages of HIV disease.
Since, as described above, R5 HIV-1 was initially
thought to be “macrophage-tropic”, macrophages were
first considered to be the infected gatekeepers which
select for R5 HIV-1 in cases of intravenous HIV-1 trans-
mission when the mucosal barriers are circumvented
[166,167]. Although macrophages are thought to be an
important HIV-1 reservoir, studies of the early stages of
HIV-1 infection indicate that lymphocytes (which do
not discriminate between X4 and R5), rather than
macrophages, are the first HIV-1 targets [94,95,97,126].
However, macrophages do become infected and these
cells along with other antigen-presenting cells (APCs)
are less susceptible to cytotoxic T lymphocytes than are
infected T cells. This has been clearly demonstrated in
animal models [168,169]. As a result of this and other
factors, infected macrophages survive longer than lym-
phocytes, disseminating R5 HIV-1 with which they are
predominantly infected. Although the tissue explant
model seems to be closer to the situation in vivo than
isolated cell cultures, it has its own limitations [127]. In
laboratories, explant models are infected by HIV-1 sus-
pensions, while in vivo it seems that virus is also disse-
minated from cell to cell through the viral synapses.
Through these synapses R5 HIV-1 is selectively trans-
mitted from DCs to resting CD4+ T cells [170].
Finally, it seems that in vivo some systemic factors
exist that are more restrictive for X4 than for R5 HIV-1.
The first candidate for such a factor is the immune
response, including the innate one. Both X4 and R5
HIV-1 induce cytokines, including RANTES and SDF-1
[171], that bind to the respective HIV-1 coreceptors and
may prevent infection by corresponding X4 or R5 HIV-
1. In lymphoid tissue explants X4 triggers secretion of
RANTES in concentrations sufficient to suppress R5
HIV-1, however R5 infection does not induce sufficient
SDF-1 to suppress X4 HIV-1 infection [171]. Thus,
rather than explaining the gatekeeping mechanism,
these experiments indicate one of the potential factors
responsible for the “switch” of dominance from R5 to
X4 HIV-1 at the later stages of the disease.
However, in experiments with rhesus macaques that
have been inoculated with both R5 and X4 viruses
(SHIV), R5 outcompeted X4 SHIV [169]. Also, reports
have shown that one of the conserved gp120-neutraliza-
tion epitopes [172] is cryptic in R5 but is accessible in
X4 HIV-1. These and other immune mechanisms may
selectively suppress X4 HIV-1 preventing rapid evolu-
tion of X4 from R5 HIV-1. Indeed, R5 and X4 HIV-1
variants have been described that differ from each other
by only a few amino acids [173] suggesting they should
easily evolve in the absence of any X4 gatekeeping. The
in vivo mechanisms against X4 HIV-1 are so pervasive
that in 50% of individuals infected with clade B HIV-1,
X4 never evolves and viruses retain their R5 phenotype
despite progression to AIDS [174]. Moreover, although
CXCR4-utilizing HIV-1-a variants have been reported
for other clades, there is a relative lack of such variants
among non-B subtypes (especially of C and D clades)
despite aggressive progression of HIV disease [175].
Transmitted/ founder virus: Another level of
gatekeeping?
While the selective transmission of R5 over X4 virus,
irrespective of the route of transmission has been recog-
nized for sometime, more recent studies of transmitted
founder (TF) virus have suggested that there may be
additional levels of gatekeeping amongst R5 viruses
themselves. Detailed sequence analysis of virus in acute
infection has enabled investigators to determine the
sequence of virus associated with transmission [176].
These studies have shown that in <80% of transmissions,
infection is initiated by a single TF virus [7,177,178].
This apparent bottleneck can be reduced by inflamma-
tion leading to a higher frequency of multi-variant trans-
missions of 2-10 viruses [91]. Rectal transmission also
seems to mitigate the genetic bottleneck observed in
cervico-vaginal transmission [179]. However, irrespective
of the route of transmission the majority of these iso-
lates are R5, with a few displaying R5X4 phenotype
[7,177]. These data reinforce the concept of gatekeeping
against X4 virus. Nevertheless, such gatekeepers may
not be absolute, as low frequency (4%) X4 transmission
has been seen in some studies [165].
More recently there has been an increased focus on
determining whether TF virus exhibits certain phenotypic
and or molecular signatures. The first striking observation
is that while TF viruses are exclusively R5, they show
extremely poor infectivity for in vitro derived macrophages
[7]. While this needs to be confirmed using tissue macro-
phages these early observations suggest that transmission
selects for T cell tropic R5 variants. This phenotypic
observation fits with parallel studies in human mucosal tis-
sue explants [90,128,132,180] and studies delineating the
initial target cells of infection in the macaque model [94],
all of which implicate CD4 T cells as the initial targets for
infection. Furthermore, macaque studies suggest that
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TF to infect resting CD4 effector memory T cells [94].
However, whether this represents a gatekeeper against
macrophage tropic R5 virus is debatable, as T cell tropic
R5 virus is the dominant phenotype in semen of infected
individuals and indeed isolation of macrophage tropic
HIV-1 in lymph nodes, blood and semen is rare [181].
The second observation, reported in several studies, is
the apparent transmission of R5 virus with reduced N-
linked glycosylation [182-184]. HIV-1 is known to cloak
its envelope protein in N-linked oligomannose to reduce
antibody recognition [185]. At first glance such an appar-
ent reduction in glycosylation is perplexing as this poten-
tially renders TF virus more susceptible to antibody
neutralization. However such neutralization is not
expected to occur for primo HIV-1-exposure and should
only hinder HIV-1 transmission in repeatedly exposed
recipients. Only a systematic comparison of TF isolated
from subjects infected after a single or repeated exposure
could answer this question. Therefore there must be
additional gatekeepers at play that select reduced glycosy-
lation in spite of the consequential increase in suscept-
ibility to antibody neutralization. Current thinking
proposes two possible mechanisms that may not be
mutually exclusive. The first relates to the role of
N-linked glycosylation in the binding of HIV-1 to C-type
lectins. The group of van Kooyk first observed that the
C-type lectin DC-SIGN expressed on dendritic cells
could bind virus via oligomannose residues expressed on
the viral envelope [186]. Such capture of virus can facili-
tate both direct infection of dendritic cells (cis-infection)
and infection of interacting CD4 T cells (trans-infection).
This led to the rapid speculation that dendritic cell cap-
ture of virus may be an important step in the transmis-
sion process. Activation of these cells (potentially by
HIV-1 itself) is known to stimulate rapid migration to
draining lymph nodes, thereby disseminating virus to an
environment rich in activated CD4 T cells [187]. How-
ever the interaction of HIV-1 with C-type lectins turned
out to be more complex. DC-SIGN is now only one of
several C-type lectins (including Langerin) shown to bind
HIV-1 and, while under certain conditions this may favor
infection, such binding also facilitates viral uptake, degra-
dation and antigen presentation [188]. In vitro only
5-10% of viral uptake by dendritic cells evades destruc-
tion by remaining in a tetraspanin-rich compartment but
it is unclear whether this accurately reflects processing of
virus by tissue dendritic cells. Indeed it has been shown
that binding of HIV-1 by the C-type lectin langerin on
Langerhans cells provides an efficient mechanism for
viral degradation [189]. As these cells are highly abun-
dant in stratified epithelium of genital mucosas, the
absence of critical oligomannose residues could provide a
selective advantage by avoidance of triggering the cells
that define the interface between innate and adaptive
immunity. Avoidance of mechanisms that would stimu-
late cellular and humoral immune responses may be
more important to the establishment of infection than
the potential increased sensitivity to neutralizing antibo-
dies. Clearly this makes sense in a naïve susceptible
population that would have no pre-existing immunity,
however this also opens up a window of potential vulner-
ability to vaccine induced neutralizing antibodies that
could be expressed at mucosal surfaces.
An alternative hypothesis has been recently proposed
by Anthony Fauci [190]. His team was the first to iden-
tify that the HIV-1 envelope of certain viruses could
bind to the alpha-4 beta-7 gut homing integrin [191].
While not essential for infection, this integrin is
expressed on a subset of highly susceptible CD4 T cells
that express high levels of CCR5 and low levels of
CXCR4 and are concentrated in intestinal and, to a les-
ser extent, cervical mucosa. This preferential binding to
alpha-4 beta-7 cells is thought to be an important factor
in concentrating early viral replication in the intestinal
tract of infected individuals, leading to the massive loss
of CD4 T cells within this compartment in the first few
weeks of infection [192]. Dr. Fauci has proposed that TF
virus binds more efficiently to alpha-4 beta-7 cells than
those in chronically infected subjects. This difference in
binding was shown to be associated with decreased gly-
cosylation within the V1, V2 region of the HIV-1 envel-
ope, putative binding sites for alpha-4 beta-7 [190]. The
suggestion being that glycosylation may block the alpha-
4 beta-7-mediated virus binding to this highly suscepti-
ble population of CCR5 CD4 T cells. Nevertheless,
reported differences in N-linked glycosylation patterns
between TF virus and later isolates are not universally
accepted with a number of studies reporting no reduc-
tion in glycosylation [193]. It will be interesting to see
whether differences in glycosylation may be influenced
by differences in exposure of the native trimer to cellu-
lar glycosylation enzymes during de novo viral produc-
tion. Glycosylation may vary according to the phenotype
of infected cells [185]. This raises yet another question
about transmitted viruses and potential gatekeeping
mechanisms as it shifts the spotlight from a virus
d e f i n e db yi t sg e n e t i cm a k eu p ,t ot h ec e l l sw h i c hp r o -
duced the infecting virus. Despite such apparent discre-
pancies there is a growing consensus that not all R5
virus are equal in terms of transmission fitness suggest-
ing that there are further gatekeepers to be discovered.
The multiple barrier principle
Where is the main gatekeeper that selects R5 over X4?
As discussed above many multiple barriers have been
identified. However, no single barrier appears to explain
the almost perfect selection of R5 over X4 in HIV-1
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not exist [194]. Rather that the superimposition of mul-
tiple weak and imperfect barriers is sufficient to protect
against X4 HIV-1 infection. Indeed, X4 HIV-1, asso-
ciated with accelerated progression to AIDS, only
appears late in the course of the disease, and then only
in 50% of individuals infected with Clade B virus. Indeed
the majority of patients progress to AIDS in the absence
of X4 evolution. These observations suggest a sustained
selective pressure against X4 over R5 replication. A sin-
gle Big Barrier would be more fragile and breachable by
multiple mechanisms including trauma, mutations,
transformations etc, likely to provide an all or nothing
effect. Thus it seems that sequential barriers of low effi-
ciency would not only be more protective but would
provide ongoing suppression of X4 over R5 replication
within an infected individual.
This can be illustrated by a simple model consisting of
only five sequential barriers each having a selective coef-
ficient of 5 that is the probability ratio for R5 and X4 to
penetrate an individual barrier is 5:1. (Figure 1). In this
over-simplified construction, although selection of an
Figure 1 A set of imperfect multiple barriers provides gatekeeps against HIV-1 better than a single “perfect” barrier (adapted from
[194]). (a)A“perfect” barrier protects against X4 HIV-1 (left panel). If this barrier is breached (right panel), there is no protection against X4 HIV-1
infection. (b) A series of ‘imperfect’ barriers (left panel), each of which protects against X4 virus infection only five times more efficiently than against R5
HIV-1. Nevertheless the chance for X4 HIV-1 to penetrate these barriers is 3125 times lower than for R5. If one of the barriers is breached, (right panel)
the system retains relatively high selectivity: The chance for X4 HIV-1 to penetrate the barriers is still 625 times lower than for R5 HIV-1.
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tection against X4 penetration, five sequential barriers
provide a probability of 3,125 :1. Even if one of these
five barriers is breached and becomes equally permissive
to X4 and R5 HIV-1, the selective power of the con-
struction still remains high at 625:1. It is reasonable to
think that the human body has many more than five
barriers. Also, their selective power against X4 vs. R5
HIV-1 may be much higher than the 5 described in the
above modeling. Although in vivo not all of these bar-
riers may be sequential and/or independent, together
they are sufficient to protect against X4.
The number of potential barriers may be high and
redundant while their efficiency may vary between dif-
ferent individuals. Such a system would make the gate-
keeping mechanisms very individualized. Indeed, if in
one individual only a few existing barriers against HIV-1
are needed to ensure perfect gatekeeping against X4
HIV-1, in another individual the set of these selective
barriers may be different. Nevertheless the net result of
the combined gatekeeping of these barriers against X4
HIV-1 would be the same for both individuals. If the
number of barriers is large, the huge number of indivi-
dual variations would make the study of the gatekeeping
mechanism very complicated. In this case, identification
of individual barriers would require study of large
cohorts to reach statistical power.
Conclusions
In conclusion, we think that the principle of multiple
barriers is more general and is not restricted to protec-
tion against X4 HIV-1 but rather can be applied to
other phenomena when one factor has a selective advan-
tage over the other(s). In the case of X4/R5 gatekeepers,
the task of future experiments is to identify each and
every one of the selective gatekeepers and decipher their
molecular mechanisms. Knowledge of the gatekeepers‘
localization and function may enable us to facilitate
existing barriers against R5 transmission and to erect
the new ones against all HIV-1 variants.
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